SOURCE: Crucell N.V.

January 31, 2007 08:08 ET

Crucell to Release 2006 Earnings on Tuesday, February 13, 2007

LEIDEN, NETHERLANDS -- (MARKET WIRE) -- January 31, 2007 --


PRESS RELEASE

Crucell to Release 2006 Earnings on Tuesday, February 13, 2007

Leiden, The Netherlands, 31 January 2007 - Dutch biotechnology company Crucell N.V. (Euronext, NASDAQ: CRXL, Swiss Exchange: CRX) today announced that it will release its full-year 2006 financial results on Tuesday, February 13, 2007 at 08:00 Central European Time (CET) (02:00 US Eastern Daylight Time).

At 14:00 CET, Crucell will conduct a conference call open to all which will also be webcast. To participate in the conference call, please call one of the following numbers 10 minutes prior to commencement:

                   1-888 495 6452 for the US;
                       0800 358 5261- for the UK; and
                       0800 265 85 31 for the Netherlands.

Following a presentation of the results you will be able to ask
questions during a question and answer session.
The live audio webcast can be accessed via the homepage of Crucell's website at www.crucell.com, and will be archived and available for replay following the event.

About Crucell

Crucell N.V. (Euronext, NASDAQ: CRXL; Swiss Exchange: CRX) is a biotechnology company focused on research, development and worldwide marketing of vaccines and antibodies that prevent and treat infectious diseases. Its vaccines are sold in public and private markets worldwide. Crucell's core portfolio includes a vaccine against hepatitis B, a fully-liquid vaccine against five important childhood diseases, and a virosome-adjuvanted vaccine against influenza. Crucell also markets travel vaccines, such as the only oral anti-typhoid vaccine, an oral cholera vaccine and the only aluminium-free hepatitis A vaccine on the market. The Company has a broad development pipeline, with several Crucell products based on its unique PER.C6® production technology. The Company licenses this and other technologies to the biopharmaceutical industry. Important partners and licensees include DSM Biologics, sanofi aventis, GSK and Merck & Co. Crucell is headquartered in Leiden (the Netherlands), with subsidiaries in Switzerland, Spain, Italy, Sweden, Korea and the US. The Company employs over a 1000 people. For more information, please visit www.crucell.com.

Forward-looking statements

This press release contains forward-looking statements that involve inherent risks and uncertainties. We have identified certain important factors that may cause actual results to differ materially from those contained in such forward-looking statements. For information relating to these factors please refer to our Form 20-F, as filed with the U.S. Securities and Exchange Commission on July 6, 2006, and the section entitled "Risk Factors". The Company prepares its financial statements under generally accepted accounting principles in the United States (US GAAP) and Europe (IFRS).

For further information please contact:

Crucell N.V.                 For Crucell in the US:
Leonard Kruimer              Redington, Inc.
Chief Financial Officer      Thomas Redington
Tel. +31-(0)71-524 8722      Tel. +1 212-926-1733
Leonard.Kruimer@crucell.com  tredington@redingtoninc.com

Barbara Mulder
Tel: 31-(0) 71 524 8718
barbara.mulder@crucell.com

Copyright © Hugin ASA 2007. All rights reserved.

Contact Information